Altre lingue Scopus BioPharma Inc.

Azioni

SCPS

US8091711015

Mercato chiuso - OTC Markets Altri mercati azionari 20:32:13 30/11/2023			Variaz. 5gg	Var. 1 gen.
0,0520 ^USD	+1,96%		+4,00%	-46,67%

07/11	Scopus BioPharma Inc. Presenta DUET-102 in combinazione con il blocco PD-1, che dimostra un'attività antitumorale significativa in modelli di glioma maligno	CI
11/08	Scopus BioPharma Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 giugno 2023	CI

Altre lingue

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Registrazione 100% gratuita

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer	07/11
Scopus BioPharma Inc. Presents DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma	07/11
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	02/11
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	02/11
Scopus BioPharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08
Scopus BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05
Scopus BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04
Scopus BioPharma Inc. Auditor Raises 'Going Concern' Doubt	14/04
Scopus BioPharma Inc.(NasdaqCM:SCPS) dropped from S&P TMI Index	21/12
SCOPUS BIOPHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	16/12
Scopus BioPharma : Failure to Satisfy Listing Rule - Form 8-K	16/12
Scopus BioPharma Inc.(NasdaqGM:SCPS) dropped from NASDAQ Composite Index	16/12
Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower	15/12
Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move Lower	15/12
Top Premarket Gainers	15/12
SCOPUS BIOPHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	02/12
SCOPUS BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	21/11
Scopus BioPharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer	10/11
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer	10/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Transcript Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Scopus BioPharma Inc.

Azioni

SCPS

US8091711015

Altre lingue

Filtri